AX-0810
Undisclosed rare disease
Key Facts
About ProQR Therapeutics
ProQR Therapeutics is a clinical-stage biotech pioneering a novel RNA base editing platform called Axiomer. The company leverages the body's own ADAR enzyme machinery to correct RNA sequences, aiming to treat genetic disorders that are currently untreatable. Its pipeline includes both internal programs and a significant partnership with Eli Lilly, targeting a range of severe diseases. ProQR is a public company, driven by a patient-focused mission and led by a founder-CEO with a personal connection to rare disease.
View full company profileAbout ProQR
ProQR Therapeutics is a mission-driven, clinical-stage biotechnology company dedicated to developing life-changing RNA therapies for severe rare and common genetic diseases. Its core achievement is the invention of the Axiomer® RNA editing platform, a next-generation technology enabling precise single-nucleotide correction, which has attracted a major multi-target collaboration with Eli Lilly. The company's strategy is to advance its internal pipeline in ophthalmology while leveraging partnerships to expand the application of Axiomer into new therapeutic areas like the liver and central nervous system, aiming to establish clinical proof-of-concept and build a sustainable, platform-based biotech.
View full company profileTherapeutic Areas
Other Undisclosed rare disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Rare Disease Program | PeptiDream | Discovery |